Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neurol.2017.12.005 | DOI Listing |
Pathogens
March 2024
Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiences, Wroclaw Medical University, 51-149 Wroclaw, Poland.
Vaccine
February 2024
IQVIA, Falls Church, VA, USA.
Background: Background incidence rates (IRs) of health outcomes in Lyme disease endemic regions are useful to contextualize events reported during Lyme disease vaccine clinical trials or post-marketing. The objective of this study was to estimate and compare IRs of health outcomes in Lyme disease endemic versus non-endemic regions in the US during pre-COVID and COVID era timeframes.
Methods: IQVIA PharMetrics® Plus commercial claims database was used to estimate IRs of 64 outcomes relevant to vaccine safety monitoring in the US during January 1, 2017-December 31, 2019 and January 1, 2020-December 31, 2021.
Sci Rep
November 2023
Clinic of Neurology and Neurosurgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Praxis (Bern 1994)
October 2022
Innere Medizin, Kantonsspital Graubünden, Schweiz.
Z Naturforsch C J Biosci
January 2023
Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
The COVID-19 mainly causes respiratory disorders with high infection and severe morbidity and mortality. Neurologists have concerns about potential neurological side effects, profits, and timing of COVID-19 vaccines. This study aimed to review systematically research for the COVID-19 vaccine and neurological complications.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!